(Q34611616)

3 August 2017

1 reference

title

An overview of small-molecule inhibitors of VEGFR signaling (English)

1 reference

3 August 2017

S Percy Ivy

1

1 reference

3 August 2017

Jeannette Y Wick

series ordinal

2

1 reference

3 August 2017

Bennett M Kaufman

series ordinal

3

1 reference

3 August 2017

language of work or name

English

0 references

publication date

8 September 2009

1 reference

Nature Reviews Clinical Oncology

3 August 2017

published in

1 reference

3 August 2017

volume

6

1 reference

3 August 2017

issue

10

1 reference

3 August 2017

page(s)

569-579

1 reference

https://scigraph.springernature.com/pub.10.1038/nrclinonc.2009.130

3 August 2017

exact match

0 references

cites work

Tumor angiogenesis: therapeutic implications

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.130

Vascular endothelial growth factor receptor-3 in lymphangiogenesis in wound healing

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.130

Angiogenesis: update 2005.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.130

Angiogenesis as a therapeutic target

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.130

VEGF as a key mediator of angiogenesis in cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.130

Transplacental carcinogenesis by stilbestrol

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.130

Are tumours angiogenesis-dependent?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.130

Antiangiogenesis drug design: multiple pathways targeting tumor vasculature

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.130

Vascular permeability factor, an endothelial cell mitogen related to PDGF

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.130

Biology of vascular endothelial growth factors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.130

Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.130

Angiogenesis in life, disease and medicine

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.130

Vascular endothelial growth factor as a target for anticancer therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.130

The vascular endothelial growth factor (VEGF) family: angiogenic factors in health and disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.130

Post-transcriptional regulation of vascular endothelial growth factor by hypoxia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.130

Transcriptional regulation of the rat vascular endothelial growth factor gene by hypoxia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.130

von Hippel-Lindau disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.130

Vascular endothelial growth factor and its receptors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.130

Structure and dual function of vascular endothelial growth factor receptor-1 (Flt-1).

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.130

Ligand-binding sites in Ig-like domains of receptor tyrosine kinases.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.130

Growth factor signaling by receptor tyrosine kinases

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.130

Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.130

Vascular endothelial growth factor receptors in the regulation of angiogenesis and lymphangiogenesis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.130

Vascular permeability factor/vascular endothelial growth factor induces lymphangiogenesis as well as angiogenesis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.130

Signal transduction by receptors with tyrosine kinase activity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.130

Role of tyrosine kinase inhibitors in cancer therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.130

Structural analysis of receptor tyrosine kinases

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.130

Pazopanib: a novel multitargeted tyrosine kinase inhibitor

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.130

VEGF receptor signalling - in control of vascular function

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.130

VEGF receptor signal transduction

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.130

A single autophosphorylation site on KDR/Flk-1 is essential for VEGF-A-dependent activation of PLC-gamma and DNA synthesis in vascular endothelial cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.130

Identification of tyrosine residues in vascular endothelial growth factor receptor-2/FLK-1 involved in activation of phosphatidylinositol 3-kinase and cell proliferation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.130

Akt mediates cytoprotection of endothelial cells by vascular endothelial growth factor in an anchorage-dependent manner

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.130

The mammalian ShcB and ShcC phosphotyrosine docking proteins function in the maturation of sensory and sympathetic neurons

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.130

31 March 2020

2 references

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.130

31 March 2020

12 December 2020

Sphingosine kinase mediates vascular endothelial growth factor-induced activation of ras and mitogen-activated protein kinases

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.130

Vascular Endothelial Growth Factor Induction of the Angiogenic Phenotype Requires Ras Activation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.130

VEGF activates protein kinase C-dependent, but Ras-independent Raf-MEK-MAP kinase pathway for DNA synthesis in primary endothelial cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.130

Vascular endothelial growth factor stimulates tyrosine phosphorylation and recruitment to new focal adhesions of focal adhesion kinase and paxillin in endothelial cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.130

Regulation of vascular endothelial growth factor receptor 2-mediated phosphorylation of focal adhesion kinase by heat shock protein 90 and Src kinase activities

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.130

Role of the Flt-1 receptor tyrosine kinase in regulating the assembly of vascular endothelium

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.130

Isolated lymphatic endothelial cells transduce growth, survival and migratory signals via the VEGF-C/D receptor VEGFR-3

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.130

Vascular endothelial growth factor C is required for sprouting of the first lymphatic vessels from embryonic veins

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.130

Activation of vascular endothelial growth factor receptor-3 and its downstream signaling promote cell survival under oxidative stress

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.130

Endothelial receptor tyrosine kinases activate the STAT signaling pathway: mutant Tie-2 causing venous malformations signals a distinct STAT activation response

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.130

Oncogenic kinase signalling

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.130

Protein tyrosine kinase structure and function

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.130

The protein kinase complement of the human genome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.130

The use of computational methods in the discovery and design of kinase inhibitors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.130

The development and therapeutic potential of protein kinase inhibitors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.130

VEGF/VEGFR signalling as a target for inhibiting angiogenesis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.130

Development of vascular endothelial growth factor receptor (VEGFR) kinase inhibitors as anti-angiogenic agents in cancer therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.130

Small molecule inhibitors of KDR (VEGFR-2) kinase: an overview of structure activity relationships

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.130

VEGF-targeted therapy: mechanisms of anti-tumour activity.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.130

Von Hippel-Lindau disease: clinical and molecular perspectives

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.130

Inhibitors of Raf kinase activity block growth of thyroid cancer cells with RET/PTC or BRAF mutations in vitro and in vivo

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.130

Anthranilic acid amides: a novel class of antiangiogenic VEGF receptor kinase inhibitors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.130

AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.130

Protein kinase inhibitors: the tyrosine-specific protein kinases

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.130

AMG 706, an oral, multikinase inhibitor that selectively targets vascular endothelial growth factor, platelet-derived growth factor, and kit receptors, potently inhibits angiogenesis and induces regression in tumor xenografts

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.130

AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.130

Novel 4-anilinoquinazolines with C-7 basic side chains: design and structure activity relationship of a series of potent, orally active, VEGF receptor tyrosine kinase inhibitors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.130

BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.130

Biomarkers of response and resistance to antiangiogenic therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.130

Hypertension and rarefaction during treatment with telatinib, a small molecule angiogenesis inhibitor

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.130

Results from an in vitro and a clinical/pharmacological phase I study with the combination irinotecan and sorafenib

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.130

Phase II trial of sorafenib in patients with metastatic breast cancer previously exposed to anthracyclines or taxanes: North Central Cancer Treatment Group and Mayo Clinic Trial N0336.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.130

Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.130

BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.130

Preclinical pharmacokinetics and in vitro metabolism of brivanib (BMS-540215), a potent VEGFR2 inhibitor and its alanine ester prodrug brivanib alaninate.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.130

VEGF inhibition and renal thrombotic microangiopathy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.130

Safety, pharmacokinetics, and preliminary antitumor activity of sorafenib: a review of four phase I trials in patients with advanced refractory solid tumors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.130

Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.130

Phase I trial of the oral antiangiogenesis agent AG-013736 in patients with advanced solid tumors: pharmacokinetic and clinical results

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.130

Safety, pharmacokinetics, and efficacy of AMG 706, an oral multikinase inhibitor, in patients with advanced solid tumors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.130

Phase I clinical study of AZD2171, an oral vascular endothelial growth factor signaling inhibitor, in patients with advanced solid tumors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.130

Phase I dose escalation and pharmacokinetic study of AZD2171, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinase, in patients with hormone refractory prostate cancer (HRPC)

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.130

Clinical evaluation of ZD6474, an orally active inhibitor of VEGF and EGF receptor signaling, in patients with solid, malignant tumors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.130

Phase I dose escalation study of telatinib (BAY 57-9352) in patients with advanced solid tumours

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.130

A phase I pharmacokinetic and pharmacodynamic study of TKI258, an oral, multitargeted receptor tyrosine kinase inhibitor in patients with advanced solid tumors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.130

A phase I/randomized phase II, non-comparative, multicenter, open label trial of CP-547,632 in combination with paclitaxel and carboplatin or paclitaxel and carboplatin alone as first-line treatment for advanced non-small cell lung cancer (NSCLC)

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.130

Phase I clinical and pharmacokinetic study of PTK/ZK, a multiple VEGF receptor inhibitor, in patients with liver metastases from solid tumours

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.130

A phase I study with oral SU5416 in patients with advanced solid tumors: a drug inducing its clearance

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.130

Phase I clinical and pharmacological evaluation of the multi-tyrosine kinase inhibitor SU006668 by chronic oral dosing

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.130

A phase I surrogate endpoint study of SU6668 in patients with solid tumors.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.130

Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.130

OSI-930: a novel selective inhibitor of Kit and kinase insert domain receptor tyrosine kinases with antitumor activity in mouse xenograft models

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.130

Expression of the angiogenic factors vascular endothelial cell growth factor, acidic and basic fibroblast growth factor, tumor growth factor beta-1, platelet-derived endothelial cell growth factor, placenta growth factor, and pleiotrophin in human p

31 March 2020

1 reference

12 December 2020

ZD4190: an orally active inhibitor of vascular endothelial growth factor signaling with broad-spectrum antitumor efficacy

1 reference

12 December 2020

V-SRC induces expression of hypoxia-inducible factor 1 (HIF-1) and transcription of genes encoding vascular endothelial growth factor and enolase 1: involvement of HIF-1 in tumor progression.

1 reference

12 December 2020

Purification and NH2-terminal amino acid sequence of guinea pig tumor-secreted vascular permeability factor.

1 reference

12 December 2020

Alpha-cyano-beta-hydroxy-beta-methyl-N-[4-(trifluoromethoxy)phenyl] propenamide: an inhibitor of the epidermal growth factor receptor tyrosine kinase with potent cytotoxic activity against breast cancer cells.

1 reference

12 December 2020

Phase I trial of pazopanib in patients with advanced cancer.

1 reference

12 December 2020

Inhibitors of tyrosine kinase

1 reference

12 December 2020

Dose-finding and pharmacokinetic study of cisplatin, gemcitabine, and SU5416 in patients with solid tumors

1 reference

12 December 2020

Wild-type p53 and v-Src exert opposing influences on human vascular endothelial growth factor gene expression

1 reference

12 December 2020

ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration.

1 reference

12 December 2020

Tumor-specific regulation of angiogenic growth factors and their receptors during recovery from cytotoxic therapy

1 reference

12 December 2020

10.1038/NRCLINONC.2009.130

Identifiers

DOI

1 reference

Dimensions Publication ID

3 August 2017

1031302116

0 references

1 reference